Cooperativity of Rb, Brca1, and p53 in Malignant Breast Cancer Evolution

被引:18
|
作者
Kumar, Prashant [1 ]
Mukherjee, Malini [2 ]
Johnson, Jacob P. S. [1 ]
Patel, Milan [1 ]
Huey, Bing [3 ]
Albertson, Donna G. [3 ]
Simin, Karl [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA
[2] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat Hematol Oncol, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源
PLOS GENETICS | 2012年 / 8卷 / 11期
关键词
TO-MESENCHYMAL TRANSITION; BASAL-LIKE; MAMMARY PROGENITORS; TUMOR-SUPPRESSOR; CLAUDIN-LOW; LUMINAL-B; MOUSE; INACTIVATION; SUBTYPES; MICE;
D O I
10.1371/journal.pgen.1003027
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Breast cancers that are "triple-negative" for the clinical markers ESR1, PGR, and HER2 typically belong to the Basal-like molecular subtype. Defective Rb, p53, and Brca1 pathways are each associated with triple-negative and Basal-like subtypes. Our mouse genetic studies demonstrate that the combined inactivation of Rb and p53 pathways is sufficient to suppress the physiological cell death of mammary involution. Furthermore, concomitant inactivation of all three pathways in mammary epithelium has an additive effect on tumor latency and predisposes highly penetrant, metastatic adenocarcinomas. The tumors are poorly differentiated and have histologic features that are common among human Brca1-mutated tumors, including heterogeneous morphology, metaplasia, and necrosis. Gene expression analyses demonstrate that the tumors share attributes of both Basal-like and Claudin-low signatures, two molecular subtypes encompassed by the broader, triple-negative class defined by clinical markers.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] P53, BRCA1 and breast cancer chemoresistance
    Scata, Kimberly A.
    El-Deiry, Wafik S.
    BREAST CANCER CHEMOSENSITIVITY, 2007, 608 : 70 - 86
  • [2] A novel domain of BRCA1 interacts with p53 in breast cancer cells
    Buck, Martina
    CANCER LETTERS, 2008, 268 (01) : 137 - 145
  • [3] Breast cancer in young women: Prevalence of LOH at p53, BRCA1 and BRCA2.
    Johnson, SM
    Shaw, JA
    Walker, RA
    JOURNAL OF PATHOLOGY, 2000, 192 : 3A - 3A
  • [4] Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
    SM Johnson
    JA Shaw
    RA Walker
    Breast Cancer Research, 2 (Suppl 1)
  • [5] Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer
    Okumura, Naoko
    Yoshida, Hitomi
    Kitagishi, Yasuko
    Nishimura, Yuri
    Matsuda, Satoru
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 413 (03) : 395 - 399
  • [6] Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
    Ludwig, T
    Chapman, DL
    Papaioannou, VE
    Efstratiadis, A
    GENES & DEVELOPMENT, 1997, 11 (10) : 1226 - 1241
  • [7] BRCA1/P53: Two strengths in cancer chemoprevention
    Raimundo, Liliana
    Ramos, Helena
    Loureiro, Joana B.
    Calheiros, Juliana
    Saraiva, Lucilia
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (01):
  • [8] BRCA1: a scaffold for p53 response?
    Hohenstein, P
    Giles, RH
    TRENDS IN GENETICS, 2003, 19 (09) : 489 - 494
  • [9] Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer
    Szabova, Ludmila
    Yin, Chaoying
    Bupp, Sujata
    Guerin, Theresa M.
    Schlomer, Jerome J.
    Householder, Deborah B.
    Baran, Maureen L.
    Yi, Ming
    Song, Yurong
    Sun, Wenping
    McDunn, Jonathan E.
    Martin, Philip L.
    Van Dyke, Terry
    Difilippantonio, Simone
    CANCER RESEARCH, 2012, 72 (16) : 4141 - 4153
  • [10] BRCA1 and p53 regulate critical prostate cancer pathways
    De Luca, P.
    Moiola, C. P.
    Zalazar, F.
    Gardner, K.
    Vazquez, E. S.
    De Siervi, A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (03) : 233 - 238